Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi‐modal investigation of memory performance in US POINTER
Alzheimer's & Dementia · 2026-11 · 22 (11)
DOI: 10.1002/alz.71989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 17.11.2026. Verfasst von Eva Min und 10 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute on Aging, Alzheimer's Association.
Abstract (Originalsprache)
INTRODUCTION The apolipoprotein E ( APOE ) ε4 allele is a key genetic risk factor for Alzheimer's disease (AD), but the etiology of impairment in non‐carriers is less understood. METHODS We used regression and mediation models to test the cross‐sectional relationships among APOE genotype, positron emission tomography amyloid and tau, vascular risk factors, and episodic memory within the US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ancillary imaging dataset of non‐demented older adults. RESULTS In our cohort ( N = 880), APOE ε4 carriers showed higher global amyloid, higher meta‐temporal tau, smaller hippocampal volume, poorer memory, and a stronger relationship between amyloid and tau standardized uptake value ratio (SUVR; ∆β = 0.22, p < 0.001). Tau predicted memory ( p < 0.01) and partially mediated the APOE –memory association. In a stratified analysis, higher Framingham Heart Study risk score (FHS; p = 0.022) and not tau SUVR ( p = 0.1) were associated with memory among APOE ε4 non‐carriers, whereas tau SUVR ( p = 0.048) but not FHS risk score ( p = 0.55) was associated with memory amongst APOE ε4 carriers. DISCUSSION Drivers of cognitive performance appear to be specific to APOE ε4 carrier status, emphasizing the need to identify alternative, or contributing, disease mechanisms among non‐carriers. Highlights The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is composed of older adults at elevated risk of cognitive decline and cardiovascular disease burden. Further multimodal neuroimaging data was collected through the POINTER Imaging ancillary study. At baseline evaluation, the apolipoprotein E ( APOE ) ε4 genotype was significantly associated with amyloid and tau pathology, hippocampal atrophy, and poor episodic memory performance. APOE ε4 genotype stratification analysis showed significant associations of Framingham cardiovascular risk score and smoking status with memory in non‐carriers only. Etiological pathways of dementia may differ in contributive strength to cognitive deterioration within this at‐risk cohort.
Förderung
- National Institute on Aging
- Alzheimer's Association
Zitieren
APA
Min, E., Harrison, T. M., Landau, S. M., Vemuri, P., Snyder, H., Carrillo, M. C., Baker, L., Espeland, M. A., Maillard, P., Whitmer, R. A., & DeCarli, C. (2026). Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi‐modal investigation of memory performance in US POINTER. Alzheimer's & Dementia, 22(11). https://doi.org/10.1002/alz.71989
Vancouver
Min E, Harrison TM, Landau SM, Vemuri P, Snyder H, Carrillo MC, et al. Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi‐modal investigation of memory performance in US POINTER. Alzheimer's & Dementia. 2026;22(11). doi:10.1002/alz.71989
BibTeX
@article{Min2026,
author = {Min, Eva and Harrison, Theresa M. and Landau, Susan M. and Vemuri, Prashanthi and Snyder, Heather and Carrillo, Maria C. and Baker, Laura and Espeland, Mark A. and Maillard, Pauline and Whitmer, Rachel A. and DeCarli, Charles},
title = {Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi‐modal investigation of memory performance in US POINTER},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {11},
doi = {10.1002/alz.71989}
}
EUVIMED